Entrada Therapeutics (TRDA) Q1 2026 earnings summary

Executive summary

• Advanced clinical-stage pipeline for neuromuscular and inherited retinal diseases, focusing on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), with positive topline results from ELEVATE-44-201 Cohort 1 showing favorable safety, tolerability, and early functional benefit at 6 mg/kg dose.

• ENTR-601-44 Phase 1/2 Cohort 1 met primary safety and tolerability endpoints, with significant functional improvement observed.

• Vertex partnership for VX-670 in DM1 progressing, with results expected in the second half of 2026.

• Cash, cash equivalents, and marketable securities of $254.9 million as of March 31, 2026, expected to fund operations into Q3 2027.

• On track to report ELEVATE-45-201 Cohort 1 data in mid-2026 and additional ELEVATE-44-201 data by year-end 2026.

Financial highlights

• Collaboration revenue was $0.9 million for Q1 2026, down from $20.6 million in Q1 2025 due to completion of research plan activities for VX-670.

• Research and development expenses increased to $33.1 million from $32.1 million year-over-year, driven by DMD program progress.

• General and administrative expenses were $10.1 million, slightly down from $10.3 million year-over-year.

• Net loss widened to $39.7 million from $17.3 million year-over-year.

• Cash, cash equivalents, and marketable securities decreased to $254.9 million from $295.7 million sequentially.

Outlook and guidance

• Cash runway expected into Q3 2027 based on current operating plans.

• Topline results from ENTR-601-44 Cohort 2, ENTR-601-45 Cohort 1, and ELEVATE-44-201 Cohort 1 open-label period expected by end of 2026; ELEVATE-45-201 Cohort 1 data expected mid-2026.

• Regulatory filings for ENTR-601-50 and ENTR-601-51 planned after review of ongoing study data.

• Ongoing evaluation of additional regulatory applications and expansion of ocular pipeline.

• Anticipates increased R&D expenses as clinical and preclinical programs advance.